Does ketamine cause sexual side effects like SSRIs do?

The published ketamine literature has not identified persistent sexual dysfunction as a common reported side effect, in contrast to SSRIs where rates of sexual dysfunction are well documented. Research is thinner here than for other side-effect categories, and individual experience varies. If you have specific concerns, raise them with your prescriber before starting treatment.

Can I have sex the day of an infusion?

We ask patients to wait until the post-session monitoring window has passed and the driving and decision-making restrictions have lifted, typically the next day. Follow the discharge instructions you receive at the clinic. The acute infusion-day effects are temporary, and most patients are clear-headed by the following morning.

Will my libido come back as depression lifts?

Many responders report that interest, energy, and arousal return as the depression lifts. A 2017 review in the Journal of Clinical Psychiatry by Andrade noted that effective depression treatment itself often improves sexual function, which can complicate attribution. Treating the underlying mood condition is one of the most direct ways to address libido changes that began with depression.

I'm still on an SSRI — will ketamine fix the sexual side effects from that?

Not directly. If an SSRI is the cause of sexual dysfunction, the source remains the SSRI itself. Ketamine works on a different system, the glutamate and NMDA pathway, so adding ketamine does not remove SSRI-related side effects. If the side effects are intolerable, the conversation to have is with the prescriber about dose adjustment, switching agents, or a supervised taper. Never change SSRI dosing on your own.

Should I tell my CRNA about sexual concerns?

Yes. It is relevant to dose, medication review, and integration goals. Sexual function is a legitimate part of mental wellness, and bringing it up helps the clinical team build a more complete picture of what you want treatment to address. The intake conversation is private and confidential.

Ketamine and Sexual Function: What Patients Actually Ask

Why this question rarely gets asked out loud

Sexual function comes up in almost every consultation, eventually. Rarely first. People ask about cost, about dissociation, about whether they will need a driver. They ask about the chair and the lighting and what the room feels like. Then, sometimes near the end, sometimes only after the second visit, they ask the question they actually came in with: will this affect my sex life, the way the SSRI did?

It is a fair question and a common one. The answer is more nuanced than most patients expect, partly because the published literature on ketamine and sexual function is genuinely thinner than the literature on, say, ketamine and blood pressure or ketamine and dissociation. We will not pretend more is known than is known. But we will lay out what the research actually says, what patients in our clinic tend to report, and what to bring up with the prescriber who knows your medication history.

Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and chronic pain is off-label. That framing matters here, because it shapes what kind of side-effect data is and is not available.

What SSRIs do to sexual function — the comparison patients are making

To understand why the ketamine question gets asked at all, you have to understand what SSRIs commonly do. Sexual dysfunction is one of the most frequent and most under-discussed side effects of selective serotonin reuptake inhibitors. The category includes reduced libido, delayed or absent orgasm, erectile dysfunction, reduced lubrication, and a kind of emotional muting around intimacy that patients often describe as feeling disconnected from themselves.

A 2009 meta-analysis by Serretti and Chiesa in the Journal of Clinical Psychopharmacology pooled data across SSRI and SNRI trials and found that drug-induced sexual dysfunction occurs at rates substantially higher than placebo, with estimates in the broader literature ranging widely depending on how the question is asked. When patients are asked directly and confidentially, reported rates often land somewhere in the thirty-to-sixty-percent range across the SSRI class, which is far higher than what gets captured in routine clinical visits where no one asks at all.

The same meta-analysis flagged sexual dysfunction as a frequent driver of treatment discontinuation. That is the part most patients know intuitively. They quit the medication, the side effect resolves for many but not all, and they go looking for another option. Ketamine is sometimes that next stop. Many of them have already read our article on ketamine and SSRI discontinuation before they ever pick up the phone.

What the ketamine literature actually says

Here is where we have to be careful. The ketamine literature has not catalogued persistent sexual dysfunction as a common reported side effect, but the data on this specific question is thinner than the data on dissociation, blood pressure changes, or transient nausea.

Short and colleagues published a systematic review in Lancet Psychiatry in 2018 that synthesized adverse-event reporting across the major ketamine-for-depression trials. The catalogued side effects were the ones you would expect — dissociation, dizziness, transient blood pressure elevation, mild nausea, headache, blurred vision — and these typically resolved within a couple of hours of the infusion ending. Persistent sexual dysfunction was not among the commonly reported adverse events. That is not the same as saying ketamine never affects sexual function in any individual; it means the systematic signal that exists for SSRIs does not appear in the ketamine literature at the population level.

For more on the broader evidence base supporting ketamine in mood disorders, see our overview of ketamine for treatment-resistant depression.

Acute vs. ongoing effects: the day-of vs. the week-after

It helps to separate the acute infusion-day window from the days and weeks that follow. They behave differently.

On the day of the infusion, ketamine produces a dissociative state, mild sedation, and a several-hour window during which decision-making, driving, and operating equipment are all off the table. We do not recommend sex during the post-session window for the same reasons we do not recommend driving. Coordination, judgment, and consent capacity all need to be fully back online. Most patients are clear-headed by the next morning.

Beyond the acute window, ongoing effects on sexual function are not commonly reported in the literature. Some patients describe a sense of emotional re-engagement that, for them, includes a return of interest in physical intimacy. Some describe no change. A small number describe things that surprise them, in either direction. Individual experience varies, and we treat that as a normal part of the range.

The depression-lifts-libido-returns pattern

One of the most useful framings comes from Andrade, writing in the Journal of Clinical Psychiatry in 2017. The point Andrade made, summarizing a body of evidence, is that effective treatment of depression itself often improves sexual function. Depression suppresses libido, blunts arousal, and shrinks interest in pleasure of all kinds. When the depression lifts, those things tend to come back.

This complicates attribution in a useful way. If a patient on an SSRI experiences sexual dysfunction, some of that is the medication and some of it is the underlying depression. If a patient on ketamine experiences a return of libido, some of that is the lifting of depression and not necessarily a unique sexual effect of ketamine itself. The honest answer is that we are looking at a tangled set of contributors and that treating the mood condition tends to be the most direct lever for libido changes that began with the depression.

For patients who responded to ketamine after years of SSRI-related sexual flattening, the felt experience is often that something came back online. Whether to credit the ketamine, the lifting depression, or the eventual reduction in SSRI dose under their prescriber's supervision is a question for the chart, not the marketing copy.

Who should still be cautious

A few specific situations call for extra care. Patients on multiple psychiatric medications — particularly combinations involving SSRIs, MAOIs, lithium, or stimulants — should review the full medication list with the prescriber and the clinic before starting. Our article on ketamine medication interactions walks through the categories that warrant the most attention.

Patients with post-SSRI sexual dysfunction (PSSD) — a condition in which sexual side effects persist after the SSRI has been discontinued — are a population the literature has not specifically studied with ketamine. We will not promise that ketamine resolves PSSD, because the evidence to support that claim does not exist. We will not rule it out either. Anyone in this situation should talk to a clinician who has worked with PSSD patients and approach treatment with realistic expectations.

Patients with hypertension, cardiac history, or pelvic pain conditions should disclose those during the intake conversation. None of them are automatic disqualifiers, but they shape the dosing and the monitoring plan.

Talking to a prescriber when this is the real question

If sexual side effects are a major reason you are looking at ketamine, the most important conversation is with the clinician who manages your psychiatric medications. We are not in a position to recommend stopping, starting, or changing an SSRI. That call belongs to your prescriber, who knows your full history, your relapse risk, and your treatment goals. Our job is to clarify what ketamine can and cannot reasonably be expected to do, and to coordinate with your team where appropriate.

If you do not currently have a prescriber, or if your prescriber is not familiar with ketamine, our piece on what to tell your PCP about ketamine may help bridge the conversation. Understanding how the consultation process works at our clinic can also reduce anxiety about bringing this up at all.

When to bring it up in integration

A practical note for patients in active treatment. Integration — the work of making sense of what happened during sessions and applying it to daily life — is the right place to surface intimacy and sexual function questions if they come up. Some patients find the dissociative state surfaces material that is intimate in nature. Some find that as depression lifts, the previously frozen parts of their lives begin to thaw, and questions about partnership, attraction, and embodiment come back onto the table.

Bring this material to your integration provider, your therapist, or your CRNA at the next session. It is relevant to dose, medication review, and the goals you set for treatment. You will not be the first patient to bring it up, and you will not be the last. It is a normal part of the clinical conversation.

For context on what each session itself looks like, our overview of common ketamine myths addresses several of the questions patients tend to carry into the room.

Ketamine and Sexual Function: What Patients Actually Ask (and What the Research Shows)